NLS Pharma: More than doubles on Novartis license deal

NewcelX AG

12/03/2021 15:50

** Shares of Swiss pharmaceuticals maker  NLSP.O  jump as
much as 160.4% to a record high of $7.35
    ** Co says it entered a license deal with Swiss pharma firm
Novartis  NOVN.S  for full regulatory data for Mazindol, an
appetite suppressant; License is on an exclusive basis in the
U.S.  urn:newsml:reuters.com:*:nPn6pdp7ka
    ** NLSP says deal to help advance its development of
Quilience, a controlled release formula of Mazindol, which is
being developed to treat narcolepsy
    ** Stock set for its best day ever; down 2% since listing in
January, as of Thursday's close 

 (Reporting by Ambar Warrick in Bengaluru)
 ((Ambar.Warrick@thomsonreuters.com; +91-80-6182-2837; Reuters
Messaging: ambar.warrick.thomsonreuters.com@reuters.net;
Twitter: @AmbarWarrick))